SGFG
CRVS icon

Silver Grove Financial Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Silver Grove Financial Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30 Buy
+2
New +$28 ﹤0.01% 2425

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Silver Grove Financial Group's CRVS Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 2 shares worth $30. The stake represents ﹤0.01% of the portfolio and ranks #2425 among its holdings.

174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Silver Grove Financial Group held 2 shares of Corvus Pharmaceuticals worth $30 as of Q2 2026.
  • Corvus Pharmaceuticals was a new Silver Grove Financial Group position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2425 holding.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.